| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board
|
|
ii
|
|
|
|
O1 Serum IL-6 level as a marker of disease activity in ankylosing spondylitis patients with pure axial involvement only
|
Shefali K Sharma,
Shaheen Ahmad
|
S1
|
|
|
|
O2 Translation, cultural adaptation and validation of Bath questionnaires and HAQ-S in Hindi for Indian patients with ankylosing spondylitis
|
Varun Dhir,
Sujay Kulkarni,
Ashish Adgaonkar,
Poornima Dhobe,
Amita Aggarwal
et al.
|
S1
|
|
|
|
O3 Increased bone turnover in ankylosing spondylitis is associated with hypovitaminosis D and low bone mineral density
|
S Shankar,
Y Uday,
M Pasha,
A Handa
|
S1
|
|
|
|
O4 Source of anti-citrullinated peptide antibodies in rheumatoid arthritis— preclinical disease may begin in the periodontal pockets*
|
P Damodaram,
Meghana Arunachalam,
H Shabina,
L Rajasekhar,
M Bhanumoorthy,
G Narsimulu
et al.
|
S1
|
|
|
|
O5 Persistent expression and function of multidrug resistance protein-1 in rheumatoid arthritis predicts resistance to methotrexate*
|
BN Shiva Prasad,
Deepak Tripathi,
Mohit Kumar Rai,
Vikas Agarwal
|
S1-S2
|
|
|
|
O6 Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow mediated vasodilatation and their response to therapy with disease-modifying anti-rheumatic drugs*
|
Maitrayee Chatterjee Adhikari,
Aharna Guin,
Pradyot Sinhamahapatra,
Alakendu Ghosh
|
S2
|
|
|
|
O7 To determine the prevalence and clinically significant cut-off titre of anti-cyclic citrullinated peptide antibody in the diagnosis of early rheumatoid arthritis in Indian population
|
Parasar Ghosh,
Jana Debarshi,
Dhar Sanjay,
Ghosh Alakendu
|
S2
|
|
|
|
O8 Change in pain pressure threshold reflects disease activity but does not correlate to inflammatory parameter in rheumatoid arthritis
|
MS Arun,
S Chandrashekara,
KP Suresh
|
S2
|
|
|
|
O9 Clinical profile of primary Sjogrens syndrome with renal tubular acidosis
|
P Sandhya,
Nihal Thomas,
Simon Rajaratnam,
Debashish Danda
|
S2-S3
|
|
|
|
O10 Serum alanine amino transferase—a disease activity marker in inflammatory myositis?
|
Ruchika Goel,
Debashish Danda,
CE Eapen,
Sathish Kumar
|
S3
|
|
|
|
O11 Outcome measures in idiopathic inflammatory myositis
|
S Vidya,
S Rukmangatharajan,
S Balameena,
D Theresa Mary,
R Ragunathan
et al.
|
S3
|
|
|
|
O12 Nested prospective open case–control comparative study of intra-articular injection of low-dose versus high-dose viscosupplement given with and without an aid of image intensifier and the frequency of use when given with and without steroid in osteoarthritis of knees
|
P Samikrishnan
|
S3
|
|
|
|
O13 Advanced glycation end-product inhibition beneficial in osteoarthritis—a randomised double-blind placebo-controlled study
|
A Syngle,
K Vohra,
S Garg,
P Gupta
|
S3-S4
|
|
|
|
O14 Impact of aberrations in xenobiotic metabolism on the susceptibility to systemic lupus erythematosus
|
Yedluri Rupasree,
Addepalli Pavani,
L Rajasekhar,
Shaik Mohammad Naushad,
Vijay Kumar Kutala
et al.
|
S4
|
|
|
|
O15 Effect of TLR4 (Asp 299Gly), TLR9 (T1237C) and CD14 (C159T) gene polymorphism and susceptibility to SLE
|
Bidyut Das,
Aditya Panda,
Rina Tripathy
|
S4
|
|
|
|
O16 Urinary and serum MCP-1 and IP-10 are good markers to assess lupus activity*
|
Bonnie Abujam,
Satyanarayana Swamy,
Amita Aggarwal
|
S4
|
|
|
|
O17 T-cell regulatory genes (PTPN22 and CTLA-4) polymorphism in granulomatosis with polyangitis (Wegener's granulomatosis)*
|
L Rani,
A Sharma,
RW Minz,
D Gupta,
NK Panda,
VK Sakhuja
et al.
|
S4-S5
|
|
|
|
O18 ANCA-associated vasculitis: experience over eight years
|
S Nagaraj,
PN Joshi,
A Buche,
G Mangat,
C Balakrishnan
et al.
|
S5
|
|
|
|
O19 Gene expression profiling in ERA show involvement of innate immune system
|
Amita Aggarwal,
A Myles,
A Tuteja
|
S5
|
|
|
|
O20 Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in persistent chikungunya arthritis: a 24-week randomised controlled study
|
Vinod Ravindran,
George Alias
|
S5
|
|
|
|
O21 Hydrostatic distension for frozen-shoulder pressure-volume readings
|
Viju Daniel,
PR Boopalan,
Samuel Chittaranjan
|
S5
|
|
|
|
P1 Fibromyalgia: is it rare in patients with ankylosing spondylitis?*
|
BN Shiva Prasad,
Ramnath Misra,
Vikas Agarwal,
Amita Aggarwal,
Able Lawrence
et al.
|
S6
|
|
|
|
P2 Hip involvement in ankylosing spondylitis: relation to disease activity and function
|
Tukaram Patil,
Lalana S Kalekar,
Amol Kamble,
Yojana A Gokhale
|
S6
|
|
|
|
P3 Effect of sulfasalazine on fertility of spondyloarthropathy patients
|
Kaushik S Bhojani,
Shubhada Kalke,
Rakesh Tank
|
S6
|
|
|
|
P4 Outcome of spondyloarthropathy patients with induction doses of infliximab
|
I Venkatesh,
S Rukmangatharajan,
TN Tamilselvam,
R Ravichandran,
T Aarthi Priya
et al.
|
S6
|
|
|
|
P5 Andersson's lesion or infective discitis?—a diagnostic dilemma
|
Vijay Rao,
Kaushik Chaudhuri,
Maggie Allen
|
S6-S7
|
|
|
|
P6 Role of MRI in undifferentiated arthritis of hand and its impact on ACR/EULAR 2010 criteria for rheumatoid arthritis—a pilot study
|
Sreedhar Vakati,
RK Paruchuri,
P Damodaram,
L Rajasekhar
|
S7
|
|
|
|
P7 Study of APOE gene and D2S439 marker in patients of rheumatoid arthritis and their correlation with severity of disease
|
LA Gauri,
B Ranwa,
K Nagar,
Q Fatima,
Rajuram,
HP Jaipal,
M Meena
et al.
|
S7
|
|
|
|
P8 The role of musculoskeletal ultrasound in the management of peripheral arthritis in a rheumatology outpatient clinic
|
Vijay Rao,
Santosh Rai,
Anupam Paul,
Kaushik Chaudhuri
|
S7
|
|
|
|
P9 Remission occurs still only in minority while a tight control is achievable
|
S Chandrashekara,
BU Priyanka
|
S7
|
|
|
|
P10 Vitamin D level in rheumatoid arthritis: correlation with the disease activity
|
AR Naidu,
P Damodaram,
S Habibi,
S Kanchinadham,
L Rajasekhar,
G Narsimulu
et al.
|
S8
|
|
|
|
P11 Subclinical renal involvement in rheumatoid arthritis: a cross-sectional study
|
Mujeeb Rahman,
Rishab Misra,
Amita Aggarwal
|
S8
|
|
|
|
P12 Study of reliability of the box and block test for manual dexterity of upper extremity function in patients with rheumatoid arthritis
|
Alok Ranjan,
Lydia Edward,
Dilesh Kumar,
Sandhya,
Debashish Danda
et al.
|
S8
|
|
|
|
P13 A randomized trial to compare the efficacy of different treatment regimens in early rheumatoid arthritis*
|
A Batra,
U Kumar,
S Kaur,
SK Sharma,
RM Pandey,
S Hari,
R Gupta,
H Agarwal,
DP Misra
et al.
|
S8
|
|
|
|
P14 Hip involvement in adult rheumatoid arthritis
|
N Raja,
S Rukmangatharajan,
R Ravichandran,
S Balameena,
B Senthilkumar
et al.
|
S8
|
|
|
|
P15 IL-6 blockade improves endothelial dysfunction in rheumatoid arthritis
|
Ashit Syngle,
J Kaur,
P Krishan,
K Vohra,
M Chhabra,
R Malik,
L Kaur,
M Kaur
et al.
|
S8-S9
|
|
|
|
P16 Extra-articular manifestations in rheumatoid arthritis and its association with rheumatoid factor and anti-CCP
|
Prasanta Parida,
Aditya Sahoo,
Rina Tripathy,
Bidyut Das
|
S9
|
|
|
|
P17 Profile of rheumatoid arthritis at first visit to a tertiary rheumatology centre
|
Neena Chitnis,
Preeti Nagnur-Metha,
Rohini Samant,
VR Joshi
|
S9
|
|
|
|
P18 Evaluation of disease activity in rheumatoid arthritis using RAPID3 and its correlation with DAS-28 and CDAI
|
H Singh,
V Gupta,
P Talapatra,
S Ray,
H Kumar,
M Kaur
et al.
|
S9
|
|
|
|
P19 The expression of rheumatoid arthritis in Nepal a clinical study
|
Arun Kumar Gupta
|
S9
|
|
|
|
P20 Clinical profile of anti-Ku autoantibody: a cohort study from a tertiary care centre in south India
|
Ruchika Goel,
Debashish Danda,
P Sandhya,
Saritha Natarajan,
John Jude,
John Mathew,
Vishad Viswanath
et al.
|
S9-S10
|
|
|
|
P21 Cyclophosphamide vs. mycophenolate mofetil in the treatment of interstitial lung disease associated with scleroderma: preliminary results from an open label trial
|
Dhanush Thomas,
MM Devika,
Padmanabha Shenoy
|
S10
|
|
|
|
P22 Measure of association between the presence of Ro60, Ro52 and La48 auto-antibodies and various clinical manifestations
|
S Chandrashekara,
KR Anupama,
Geetha Bali,
P Renuka,
BG Dharmanand
et al.
|
S10
|
|
|
|
P23 Oral cyclophosphamide pulse therapy revisited
|
S Shwetha,
A Naresh,
MS Arun,
BG Dharmanand
|
S10
|
|
|
|
P24 Experience with rituximab in scleroderma: initial experience
|
Sabari Nath,
Padmanabha Shenoy
|
S11
|
|
|
|
P25 Prevalence and types of dermatological manifestations in mixed connective tissue disease
|
Pradyot Sinhamahapatra,
Sumit Sen,
Alakendu Ghosh
|
S11
|
|
|
|
P26 Extraglandular manifestations in primary Sjögren syndrome
|
Shilpa Reynal D'sa,
Sowmya Sathyendra
|
S11
|
|
|
|
P27 Generalized morphea—a case report
|
Shilpa Reynal D'sa,
Ramya
|
S11
|
|
|
|
P28 A clinical study to evaluate the efficacy of viscosupplementation in patients with osteoarthritis of knee
|
V Marwaha,
I Ghosh,
N Bajaj,
ND Reddy,
B Singh,
CS Narayanan,
AD Mathur
et al.
|
S11
|
|
|
|
P29 Comparison of gait variables in a control group and in patients with knee osteoarthritis at National Hospital Srilanka
|
JLR Jayalath
|
S12
|
|
|
|
P30 A study on prevalence of thyroid dysfunction in patients with systemic lupus erythemotosus
|
R Ragunathan,
S Rukmangatharajan,
TN Tamilselvam,
K Muthulakshmi,
N Raja
et al.
|
S12
|
|
|
|
P31 Indian patients with lupus nephritis respond well to the euro lupus nephritis trial protocol
|
IR Vara Prasad,
L Rajasekhar,
VNN Prabu,
H Shabina,
S Agrawal,
S Kanchinadham,
G Narsimulu
et al.
|
S12
|
|
|
|
P32 Neuropsychiatric lupus: a comparison of antiphospholipid antibody positive and negative subsets
|
R Subramanian,
Ashish Badika,
Ruchika Goel,
Jyoti Surekha,
Sunithi Alexander,
John Mathew,
Debashish Danda
et al.
|
S12
|
|
|
|
P33 Lupus nephritis: experience at a tertiary referral centre in Mumbai
|
Priyanka Kharbanda,
C Balakrishnan,
G Mangat,
J Kothari
|
S12-S13
|
|
|
|
P34 IgG subclass serum levels in Indian systemic lupus erythematosus patients
|
John Mathew,
Madhumathi,
Debashish Danda
|
S13
|
|
|
|
P35 Performance of anti-cardiolipin antibodies and lupus anticoagulant assay in lupus patients with suspected anti-cardiolipin antibody syndrome
|
P Damodaram,
CH Geetha,
Shantiveer G Uppin,
L Rajasekhar
|
S13
|
|
|
|
P36 Assessment of evidence of accelerated atherosclerosis in patients of systemic lupus erythematosus with disease duration <5 years
|
H Singh,
S Ray,
J Sen,
P Talapatra,
V Gupta,
H Kumar
et al.
|
S13
|
|
|
|
P37 Patient's beliefs about the causes of systemic lupus erythematosus (SLE)
|
B Senthilkumar,
S Rukmangatharajan,
R Ravichandran,
TN Tamilselvam,
I Venkatesh
et al.
|
S13-S14
|
|
|
|
P38 Pancreatic atrophy, a rare presentation of SLE
|
S Malviya,
S Agrawal,
R Gupta
|
S14
|
|
